204 related articles for article (PubMed ID: 17963425)
1. The Rebif new formulation story: it's not trials and error.
Jaber A; Driebergen R; Giovannoni G; Schellekens H; Simsarian J; Antonelli M
Drugs R D; 2007; 8(6):335-48. PubMed ID: 17963425
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
3. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
Portaccio E; Amato MP
CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Sanford M; Lyseng-Williamson KA
Drugs; 2011 Oct; 71(14):1865-91. PubMed ID: 21942977
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.
Giovannoni G; Barbarash O; Casset-Semanaz F; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Mult Scler; 2009 Feb; 15(2):219-28. PubMed ID: 18755819
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity comparison of interferon beta-1a preparations using the BALB/c mouse model: assessment of a new formulation for use in multiple sclerosis.
Bellomi F; Muto A; Palmieri G; Focaccetti C; Dianzani C; Mattei M; Jaber A; Antonelli G
New Microbiol; 2007 Jul; 30(3):241-6. PubMed ID: 17802901
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays.
Jaber A; Baker M
J Pharm Biomed Anal; 2007 Mar; 43(4):1256-61. PubMed ID: 17118612
[TBL] [Abstract][Full Text] [Related]
9. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Johnston J; So TY
Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
[TBL] [Abstract][Full Text] [Related]
10. Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study.
Singer B; Bandari D; Cascione M; LaGanke C; Huddlestone J; Bennett R; Dangond F;
BMC Neurol; 2012 Dec; 12():154. PubMed ID: 23216674
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interferon-beta-1a : new formulation.
McKeage K; Wagstaff AJ
CNS Drugs; 2007; 21(10):871-6. PubMed ID: 17850174
[TBL] [Abstract][Full Text] [Related]
13. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
14. Rebif(®) Quality of Life (RebiQoL): A randomized, multicenter, Phase IIIb study evaluating quality-of-life measures in patients receiving the serum-free formulation of subcutaneous interferon beta-1a for the treatment of relapsing forms of multiple sclerosis.
Bandari D; Wynn D; Miller T; Singer B; Wray S; Bennett R; Hayward B; Dangond F;
Mult Scler Relat Disord; 2013 Jan; 2(1):45-56. PubMed ID: 25877454
[TBL] [Abstract][Full Text] [Related]
15. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
16. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial.
Panitch H; Goodin DS; Francis G; Chang P; Coyle PK; O'Connor P; Monaghan E; Li D; Weinshenker B; ;
Neurology; 2002 Nov; 59(10):1496-506. PubMed ID: 12451188
[TBL] [Abstract][Full Text] [Related]
17. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
[TBL] [Abstract][Full Text] [Related]
19. In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.
Scagnolari C; Selvaggi C; Di Biase E; Fraulo M; Dangond F; Antonelli G
J Immunoassay Immunochem; 2014; 35(3):288-99. PubMed ID: 24654824
[TBL] [Abstract][Full Text] [Related]
20. Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.
Christophi GP; Christophi JA; Gruber RC; Mihai C; Mejico LJ; Massa PT; Jubelt B
J Neurol Sci; 2011 Aug; 307(1-2):41-5. PubMed ID: 21658727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
